Contradistinction between doxorubicin and epirubicin: In-vitro interaction with blood components

Journal of Pharmacy and Pharmacology

Volumn 53, Issue 6, 2001, Pages 815-821

  Ramanathan Girish, S ^a   Boroujerdi, M ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; EPIRUBICIN; HEMOGLOBIN; PLASMA PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG ADSORPTION; DRUG DISPOSITION; DRUG PROTEIN BINDING; DRUG UPTAKE; ERYTHROCYTE; ERYTHROCYTE GHOST; EXCITATION; FIELD EMISSION; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LIPOPHILICITY; PH; PLASMA PROTEIN BINDING; TEMPERATURE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BINDING SITES; BLOOD PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIFFUSION; DOXORUBICIN; EPIRUBICIN; ERYTHROCYTES; FLUOROMETRY; HEMOGLOBINS; HUMANS; HYDROGEN-ION CONCENTRATION; PROTEIN BINDING; TEMPERATURE;

EID: 0034983539     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357011776162     Document Type: Article

References (32)

1. Adsorption isotherm for doxorubicin on erythrocyte-membrane
2. Pharmacokinetics and tissue uptake of doxorubicin associated with erythrocyte membrane: Erythrocyte-ghosts vs erythrocyte-vesicles
3. Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats
4. Preliminary clinical experience with 4′-epidoxorubicin in advanced human neoplasia
5. Drugs ten years later
6. Preliminary phase 1 study of 4′-epiadriamycin
7. Comparative effects of doxorubicin and 4′-epidoxorubicin on nucleic acid metabolism and cytotoxicity in a human tumour cell line
8. Binding of anthracycline derivatives to human serum lipoproteins
9. Comparative serum protein binding of anthracycline derivative
10. A Fickian diffusion transport with features of transport catalysis. Doxorubicin transport in human red blood cells
11. Changes of activity of daunorubicin, adriamycin and stereoisomers following the introduction or removal of hydroxyl groups in the amino sugar moiety
12. Prevention of doxorubicin cardiac toxicity in the mouse by N-acetyl-cysteine
13. Metabolism of adriamycin in hepatocytes isolated from the rat and rabbit
14. Effect of 4′ doxorubicin analogues on heterotransplantation of human tumours in congenitally athymic mice
15. Determination of serum proteins by means of Biuret reagent
16. Epirubicin: A review of the pharmacodynamic and pharmacokinetic properties and therapeutic use in cancer chemotherapy
17. Lipid peroxidation and possible hydroxyl radical formation stimulated by the self-reduction doxorubiciniron (III) complex
18. Comparative activity of four anthracyclines against heterotransplanted germ cell tumour lines
19. A comparison of the lethal and kinetic effects of doxorubicin and 4′-epidoxorubicin in vitro
20. Epirubicin and doxorubicin: A comparison of their characteristics, therapeutic activity and toxicity
21. Hydroxyl radical production and DNA damage induced by anthracycline-iron-complex
22. Oxidative destruction of erythrocyte ghost membrane catalysed by the doxorubicin-iron complex
23. Electron spin resonance studies on the mechanism of adriamycin induced heart mitochondrial damages
24. Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses
25. In vitro-untersuchungen zur binding von epirubicinan humane plasma-proteine und erythrozyten: Interaktion mit dem zytoprotektivum amifostin
26. Are oxygen radicals responsible for the cardiotoxicity of doxorubicin?
27. Epirubicin: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in cancer chemotherapy
28. Age related adriamycin cardiotoxicity in children
29. Adriamicin-induced free radical formation in the perfused rat heart: Implication for cardiotoxicity
30. Pharmacokinetic-toxicodynamic relationships of adriamycin in rat: Prediction of butylated-hydroxy-anisole-mediated reduction in anthracycline cardiotoxicity